Navigation Links
Intarcia Presents Compelling 48-week Results for ITCA 650 - Data Underlines the Promise to Become the First Injection-free GLP-1 Therapy at the 47th Annual EASD Meeting in Lisbon
Date:9/14/2011

HAYWARD, Calif., Sept. 14, 2011 /PRNewswire/ -- Intarcia Therapeutics, Inc. announced today the presentation of final 48-week results from a phase 2 clinical study of ITCA 650 (DUROS® subcutaneous continuous delivery of exenatide) for the treatment of type 2 diabetes at the 47th Annual Meeting of the European Association for the Study of Diabetes in Lisbon, Portugal.

(Logo:  http://photos.prnewswire.com/prnh/20050301/SFTU126LOGO)

Results of the phase 2 study, presented by Julio Rosenstock, M.D., Director of the Dallas Diabetes and Endocrine Center at Medical City and Clinical Professor of Medicine at the University of Texas Southwestern Medical School, demonstrate that patients receiving treatment with ITCA 650 experienced substantial and sustained reductions in HbA1c, fasting plasma glucose (FPG) and body weight during the 48 weeks of treatment at all doses. ITCA 650 20 mcg/day provided improved glycemic control with the most favorable tolerability profile as a starting dose for weeks 1 through 12. Subsequent transition to ITCA 650 doses of 40, 60 or 80 mcg/day led to statistically significant reductions in HbA1c, FPG and body weight after 24 and 48 weeks of treatment.  

"While injectable GLP-1s have produced some great data, we are very excited about raising the bar and changing the game with ITCA 650's breakthrough delivery system. The 48-week phase 2 results showed excellent glucose control and weight loss together with a marked reduction in the GI AEs typically associated with injectable GLP-1s. Added to that, ITCA 650's once or twice yearly dosing schedule will virtually guarantee patient compliance and adherence," said Kurt Graves, Executive Chairman of the Board of Directors of Intarcia. "ITCA 650 holds new promise for many type 2 diabetes patients and their physicians who want meaningful glucose reductions and a favorable weight profile without the
'/>"/>

SOURCE Intarcia Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Intarcia Therapeutics, Inc. Announces Completion of Enrollment of ITCA 650 Phase 1b Study for the Treatment of Type 2 Diabetes
2. Intarcia Therapeutics Names Kurt Graves Executive Chairman to Advance Strategic Interests and Broaden Commercial Goals
3. Intarcia Presents Positive ITCA 650 Phase 2 Study Results for Type 2 Diabetes at EASD
4. Intarcia Therapeutics Executive Chairman Kurt Graves to Present at 29th Annual JP Morgan Healthcare Conference
5. Intarcia Announces Presentations of Three Clinical Abstracts at the 47th Annual Meeting of the European Association for the Study of Diabetes
6. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
7. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
8. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
9. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
10. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
11. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... ORLANDO, Fla. , Sept. 19, 2014 ... continues to grow, with the publication of two papers ... Otolaryngology – Head and Neck Surgery ... of both objective and subjective measures of sleep disordered ... therapy for the reduction in obstructive sleep apnea severity ...
(Date:9/19/2014)... -- Intarcia Therapeutics, Inc. today announced the ... candidate ITCA 650 (continuous subcutaneous delivery of exenatide) in ... at the 50 th Annual Meeting of the ... from the open-label, phase 3 FREEDOM-HBL (high baseline) trial ... with poorly controlled type 2 diabetes. The results were ...
(Date:9/19/2014)... 19, 2014 Reductions in kidney ... years in people with diabetes type 2 ... benefits for the kidneys." Australian researchers have ... 2 diabetes leads to persistent reductions in kidney failure ... The global study has found that, five and a ...
Breaking Medicine Technology:New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 2New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 3New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 4Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 2Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 3Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 4ADVANCE-ON Post-trial Observational Study: Blood Pressure Arm and Glucose Arm Results 2ADVANCE-ON Post-trial Observational Study: Blood Pressure Arm and Glucose Arm Results 3
... Innovations, Inc. (Nasdaq: YDNT ) today announced that ... live and on-demand web cast conference call on Thursday, February ... broadcast of the call will be available through InterCall at ... also be available through the Company,s website, www.ydnt.com . ...
... 27, 2011 Inovio Pharmaceuticals, Inc. (NYSE Amex: ... preventive vaccines against cancers and infectious diseases, announced today the ... 21,130,400 shares of its common stock and warrants to purchase ... shares of common stock and warrants were sold in units ...
Cached Medicine Technology:Young Innovations, Inc. Provides 4th Quarter Conference Call Details 2Inovio Pharmaceuticals Closes $24.3 Million Registered Offering 2Inovio Pharmaceuticals Closes $24.3 Million Registered Offering 3Inovio Pharmaceuticals Closes $24.3 Million Registered Offering 4
(Date:9/20/2014)... York (PRWEB) September 20, 2014 ... to grow in federal court, Bernstein Liebhard LLP ... Drug Administration (FDA) have voted overwhelmingly to recommend ... in men be subjected to further study in ... a report published on September 18th by Bloomberg.com, ...
(Date:9/20/2014)... The festival season is coming soon. The ... released luxurious cocktail dresses . A lot of sophisticated ... to launch a new promotion for its high quality clothes. ... discounted price, from 20 to 71 percent off. , ... choices. They are provided in many fashionable colors. Mary, the ...
(Date:9/20/2014)... Recently, Best Cheap Hosting USA (best-cheap-hosting-usa.com), a leading ... The new site provides the latest reviews on ... Here, people can find a lot of information ... has recommended some excellent web hosting suppliers for ... web hosting suppliers, InMotion ( http://www.best-cheap-hosting-usa.com/go/InMotion/ ), keeps ...
(Date:9/20/2014)... Los Angeles, CA (PRWEB) September 20, 2014 ... power score of 3.1 out of 5, indicating a ... research firm IBISWorld, this score reflects current and future ... negotiate from historically high prices. Other factors that negatively ... volatility in demand for construction and the moderate switching ...
(Date:9/20/2014)... September 20, 2014 The Arizona Advanced ... (MCC) is celebrating National Manufacturing Day by opening its ... machining, processing and additive manufacturing labs will be offered ... 2014 at MCC’s Southern and Dobson campus (1833 W. ... southeast Lot D. , The AzAMI at MCC was ...
Breaking Medicine News(10 mins):Health News:As Testosterone Lawsuits Grow, Bernstein Liebhard LLP Notes Overwhelming Vote Calling for Further Study of Testosterone Heart Risks 2Health News:As Testosterone Lawsuits Grow, Bernstein Liebhard LLP Notes Overwhelming Vote Calling for Further Study of Testosterone Heart Risks 3Health News:High-end Fashion Designer BellasDress Offers Luxurious Cocktail Dresses For Sophisticated Women 2Health News:Best Cheap Hosting USA Launches Its New Website And Recommends InMotion To Worldwide People 2Health News:Plumbing Construction Services Procurement Category Market Research Report from IBISWorld Has Been Updated 2Health News:Plumbing Construction Services Procurement Category Market Research Report from IBISWorld Has Been Updated 3Health News:Plumbing Construction Services Procurement Category Market Research Report from IBISWorld Has Been Updated 4Health News:National Manufacturing Day Open House at Mesa Community College Oct. 3 2
... 2008 -- A study released by researchers at the ... Universitys Mailman School of Public Health, shows that cat ... of asthma symptoms in young children at age five. ... Clinical Immunology, found that children with cats in the ...
... Tenn., May 20 Ambulatory Services of,America, Inc. ... its fourth,joint venture to provide outpatient radiation oncology ... Denton Cancer Center, LP and ASA,s,subsidiary, Radiation Oncology ... and operate a radiation therapy facility in Denton, ...
... procedures at no ... charge for treating hydrosalpinx, SAN RAMON, Calif., May 20 ... Bay Area (RSC) are,hoping to recruit between 20 to 50 women ... can cause infertility, to,receive free surgeries as a part of a ...
... Butter with Less Saturated Fat - and with Omega-3, ... SMBL ) has launched Smart Balance(R) Butter Blend ... percent real butter,and 50 percent Smart Balance(R) Buttery Spread. ... convenient stick form, meeting consumer,demand for a healthier and ...
... or survival, researchers say. , , TUESDAY, May 20 ... acute kidney injury does not reduce death, improve kidney ... new study finds. , Acute kidney injury is a ... percent to 7 percent of hospitalized patients, and 35 ...
... May 20 Mercury Computer,Systems, Inc. (NASDAQ: ... solutions for complex image, sensor, and signal,processing applications, ... Company,s business on Thursday, May 29, 2008 at ... will be,held at the New York Palace Hotel, ...
Cached Medicine News:Health News:Study reveals link among childhood allergies, asthma symptoms, and early life exposure to cats 2Health News:Ambulatory Services of America, Inc. Announces Joint Venture With Denton Cancer Center, LP 2Health News:Research Grant to Fund Free Surgeries for Women Suffering From Blocked Fallopian Tubes 2Health News:Research Grant to Fund Free Surgeries for Women Suffering From Blocked Fallopian Tubes 3Health News:New Smart Balance(R) Butter Blend Sticks Make Healthier Cooking & Baking Easy 2Health News:More Dialysis Not Better in Acute Kidney Injury 2Health News:Mercury Computer Systems to Present at the Cowen and Company 20/20 Technology-Media-Telecom Conference on May 29, 2008 2
Detection of Malarial antigen in Human whole blood....
Malaria ( P. Falciparum ) Whole Blood Strip / Cassette...
This is an antigen-capture assay intended for the detection of histidine-rich protein ll (PfHRP-ll), which is released from Malaria-infected red blood cells....
OptiMAL is a malaria test, for diagnosis and therapy control of an infection by Plasmodium species (Malaria)....
Medicine Products: